The Effect of Endurance Training in Patients With Prostate Cancer
1 other identifier
interventional
30
1 country
1
Brief Summary
The aim of the present study is to investigate the effect of endurance on PSA doubling time in prostate cancer patients with an elevation in PSA following radical prostatectomy for localized cancer. Furthermore, underlying mechanisms such as reduction in inflammatory markers and improvement in insulin sensitivity and body composition are investigated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable prostate-cancer
Started Apr 2008
Typical duration for not_applicable prostate-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2008
CompletedFirst Submitted
Initial submission to the registry
April 24, 2012
CompletedFirst Posted
Study publicly available on registry
April 25, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2012
CompletedDecember 2, 2013
November 1, 2013
4.1 years
April 24, 2012
November 29, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
PSA doubling time
2 years
Secondary Outcomes (1)
Insulin sensitivity, body composition and inflammation status
0 months, 6 months and 24 months of training
Study Arms (1)
Prostate cancer, endurance training
EXPERIMENTALProstate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
Interventions
2 years of home-based endurance training
Eligibility Criteria
You may qualify if:
- Prostate cancer patients with an increase in PSA following radical prostatectomy
You may not qualify if:
- severe cardiovascular disease
- severe arthritis
- severe neuropathy
- severe hypertension
- therapy with antidiabetic agents
- other treatment for prostate cancer than radical prostatectomy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Inge Holmlead
- Herlev Hospitalcollaborator
Study Sites (1)
Centre of Inflammation and Metabolism, Rigshospitalet
Copenhagen, Copenhagen, 2100, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bente K Pedersen
Centre of Inflammation and Metabolism, Rigshospitalet
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Administrator
Study Record Dates
First Submitted
April 24, 2012
First Posted
April 25, 2012
Study Start
April 1, 2008
Primary Completion
May 1, 2012
Study Completion
May 1, 2012
Last Updated
December 2, 2013
Record last verified: 2013-11